Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionAmeriprise Financial Inc
Latest Disclosed Ownership239,941 shares
Latest Disclosed Value $ 79,389,574
Ameriprise Financial Inc reports 32.46% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Ameriprise Financial Inc filed a 13F-HR form disclosing ownership of 239,941 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $68,551,144 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 181,137 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 32.46% during the quarter. The current value of the position is $62,504,630 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 239,941 58,804 32.46 79,390 10.22 0.0034
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 181,137 -44,742 -19.81 72,029 -30.07 0.0163
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 225,879 32,230 16.64 103,001 63.14 0.0237
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 193,649 84,513 77.44 63,136 114.25 0.0156
2025-05-14 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 109,136 -18,937 -14.79 29,469 -2.22 0.0080
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 128,073 -9,765 -7.08 30,137 -20.50 0.0077
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 137,838 -100,482 -42.16 37,910 -34.54 0.0097
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 238,320 43,595 22.39 57,912 99.00 0.0157
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 194,725 -182,934 -48.44 29,102 -59.74 0.0080
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 377,659 -328,541 -46.52 72,288 -42.20 0.0216
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 706,200 80,862 12.93 125,066 5.30 0.0411
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 625,338 422,168 207.79 118,777 191.84 0.0372
2023-05-22 2023-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 203,170 155,795 328.85 40,699 261.48 0.0133
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 203,170 155,795 40,699 0.0025
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 47,375 37,804 394.98 11,259 488.24 0.0039
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,571 -914 -8.72 1,914 24.69 0.0007
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,485 -2,167 -17.13 1,535 -24.16 0.0005
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,652 115 0.92 2,024 -2.36 0.0006
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,537 1,823 17.02 2,073 2.42 0.0006
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,714 -45,941 -81.09 2,024 -78.93 0.0006
2021-08-16 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 56,655 7,274 14.73 9,608 36.77 0.0030
2021-05-17 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 49,381 7,636 18.29 7,025 29.49 0.0023
2021-02-12 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 41,745 14,176 51.42 5,425 35.08 0.0019
2020-11-16 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,569 2,514 10.03 4,016 8.22 0.0016
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,055 11,308 82.26 3,711 148.06 0.0016
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,747 781 6.02 1,496 0.27 0.0008
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,966 46 0.36 1,492 43.60 0.0006
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,920 789 6.50 1,039 18.07 0.0005
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,131 -18,006 -59.75 880 -68.75 0.0004
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30,137 274 0.92 2,816 29.65 0.0013
2019-02-14 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 29,863 -27,186 -47.65 2,172 -56.48 0.0011
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 57,049 -47,219 -45.29 4,991 -51.40 0.0017
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 104,268 79,311 317.79 10,270 245.56 0.0045
2018-05-14 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 24,957 22,357 859.88 2,972 797.89 0.0013
2018-02-12 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,600 428 19.71 331 29.80 0.0002
2017-11-07 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,172 2,172 255 0.0001
2017-02-03 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -21,571 -100.00 0 -100.00
2016-11-08 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,571 21,571 0.00 1,462 0.0008
2016-05-12 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -16,345 -100.00 0 -100.00
2016-02-11 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,345 -1,790 -9.87 1,539 5.56 0.0009
2015-11-12 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,135 13,107 260.68 1,458 141.79 0.0009
2015-08-13 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,028 2,054 69.07 603 94.52 0.0003
2015-05-14 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,974 -6,820 -69.63 310 -67.40 0.0002
2015-02-13 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,794 -428,783 -97.77 951 -97.22 0.0006
2014-11-14 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 438,577 354,342 420.66 34,254 543.63 0.0206
2014-08-13 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 84,235 -135,276 -61.63 5,322 -63.89 0.0031
2014-05-14 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 219,511 -97,187 -30.69 14,738 -27.66 0.0089
2014-02-14 2013-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 316,698 -249,349 -44.05 20,372 -43.77 0.0123
2013-11-14 2013-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 566,047 -96,578 -14.58 36,231 76.32 0.0238
2013-08-14 2013-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 662,625 662,625 20,548 0.0142
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.